These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25293577)

  • 1. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
    Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A
    Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
    Chou LP; Hsu CW; Yang SF; Lee CT; Ou YC; Lin KC; Hu CY; Jou YC; Tsai YS; Chow NH
    Clin Genitourin Cancer; 2023 Aug; 21(4):508.e1-508.e10. PubMed ID: 37183125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of fluorescent in situ hybridization over immunohistochemistry in detection of HER2 gene in carcinoma of the urinary bladder associated with and without schistosomiasis.
    Hammam O; Wishahi M; Hindawi A; Mosaad M; Akl M; Khalil H; Al Ganzoury H; Badawy M; Elesaily K
    J Egypt Soc Parasitol; 2014 Dec; 44(3):719-31. PubMed ID: 25643513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
    Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
    Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal Lymphoid Response Status in Micropapillary Urothelial Carcinomas Diagnosed in Bladder Transurethral Resections and its Comparison with Conventional Urothelial Carcinomas.
    HacihasanoĞlu E; YÜcetaŞ U; OkÇu O; BehzatoĞlu K
    Turk Patoloji Derg; 2021; 37(1):26-31. PubMed ID: 32692402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.
    Caner V; Turk NS; Duzcan F; Tufan NL; Kelten EC; Zencir S; Dodurga Y; Bagci H; Duzcan SE
    Pathol Oncol Res; 2008 Sep; 14(3):261-6. PubMed ID: 18415713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.
    Laé M; Couturier J; Oudard S; Radvanyi F; Beuzeboc P; Vieillefond A
    Ann Oncol; 2010 Apr; 21(4):815-819. PubMed ID: 19889613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of fibroblast growth factor receptor 3 and epidermal growth factor receptors, in association with Raf-1, in urothelial dysplasia and carcinoma in situ after the Chernobyl accident.
    Romanenko AM; Morimura K; Kinoshita A; Wanibuchi H; Takahashi S; Zaparin WK; Vinnichenko WI; Vozianov AF; Fukushima S
    Cancer Sci; 2006 Nov; 97(11):1168-74. PubMed ID: 16965395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
    Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
    Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
    Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
    Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
    Vidal L; Tsao MS; Pond GR; Cohen EE; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S; Hayes DN; Ho J; Dancey J; Siu LL
    Head Neck; 2009 Aug; 31(8):1006-12. PubMed ID: 19309723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.